Drugs Made In America Acquisition Corp. (DMAAR) Total Current Liabilities (2024 - 2026)

Drugs Made In America Acquisition (DMAAR) has reported Total Current Liabilities for 3 consecutive years, with $2.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Current Liabilities rose 876.85% year-over-year to $2.9 million; the trailing twelve-month figure through Jun 2026 stood at $2.9 million (up 876.85% YoY), and the FY2025 full-year result was $376172.0, down 52.72% from the prior year.
• Total Current Liabilities climbed to $2.9 million in Q2 2026 per DMAAR's latest filing, from $376172.0 in the prior quarter.
• Across five years, Total Current Liabilities topped out at $2.9 million in Q2 2026 and bottomed at $301441.0 in Q2 2025.
• Historically, Total Current Liabilities has averaged $870314.3 across 3 years, with a median of $416391.5 in 2025.
• The sharpest annual moves came in 2025 and 2026: Total Current Liabilities sank 52.72% in 2025, then soared 876.85% in 2026.
• Over 3 years, Total Current Liabilities stood at $795669.0 in 2024, then tumbled by 52.72% to $376172.0 in 2025, then surged by 682.79% to $2.9 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $2.9 million, $376172.0, and $456611.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.